{"disease":{"id":"recurrent-or-metastatic-nasopharyngeal-carcinoma","name":"recurrent or metastatic nasopharyngeal carcinoma"},"drugs":{"marketed":[{"drug_id":"penpulimab","indication_name":"Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Penpulimab kcqx","generic_name":"PENPULIMAB","company_name":"Akeso Biopharma","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Penpulimab works by binding to the PD-1 protein on immune cells, blocking its interaction with the PD-L1 protein on cancer cells and allowing the immune system to attack the cancer."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06241599","title":"A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05126719","title":"A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":238,"lead_sponsor_name":"Shanghai Miracogen Inc.","has_results":false},{"nct_id":"NCT07070479","title":"Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":208,"lead_sponsor_name":"Ming-Yuan Chen","has_results":false},{"nct_id":"NCT06657690","title":"Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04996758","title":"Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06472713","title":"Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Ming-Yuan Chen","has_results":false},{"nct_id":"NCT01254617","title":"Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}